🟢 CervoMed is trading 6.25% up in after-hours trading with no clear catalyst identified

CervoMed is trading at $1.70, up 6.25% in after-hours trading, with no clear company-specific catalyst identified.

• CervoMed’s October 29 research announcement said its Phase 2b trial missed its primary endpoint in the overall population, while also reporting exploratory subgroup and imaging findings.
• The prior mixed trial news does not explain the after-hours gain. The broader market was sharply lower, but available evidence does not establish a market-wide reason for the move.